Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

Comparison of Unfractionated Heparin and Bivalirudin for Percutaneous Coronary Intervention for Stable Angina, Unstable Angina, and Non-ST Segment Elevation Myocardial Infarction

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02448550

Acronym

CALIFORNIA

Enrollment

250

Registered

2015-05-19

Start date

2015-05-31

Completion date

2016-06-16

Last updated

2018-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Percutaneous Coronary Intervention

Brief summary

The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Interventions

DRUGBivalirudin

DRUGUnfractionated heparin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Undergoing PCI for stable angina, unstable angina, or non-ST segment elevation myocardial infarction. 2. Age 18 years or older.

Exclusion criteria

1. Inability to obtain consent 2. Emergency cardiac catheterization for ST-segment elevation myocardial infarction.

Design outcomes

Primary

Measure	Time frame
Net adverse clinical events (composite of efficacy and safety [bleeding] endpoints)	30-days

Secondary

Measure	Time frame
all cause mortality, myocardial infarction, or unplanned revascularization for ischemia	30-days
Bleeding Academic Research Consortium grade III or V bleeding events	30-days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026